OREANDA-NEWS. April 23, 2015. Deltex Medical Group plc (LSE-AIM: DEMG), the global leader in oesophageal Doppler monitoring ("ODM"), today announces that it has established its ninth dedicated trainer account in the USA.

The new account is a highly prestigious teaching hospital in Boston, Massachusetts and is part of a healthcare system that includes six major hospitals. The decision to move forward with ODM follows a successful clinical evaluation of CardioQ-ODM+ completed in September 2014 as part of a quality improvement initiative. This initiative was focused around an evidence based enhanced recovery approach to surgery. Procurement of at least 500 probes has now been formally approved for inclusion in the hospital's 2015/16 budget year starting in October 2015. In the interim the hospital is purchasing probes on an ad hoc basis and has placed three orders of 50 probes each time over the last four months.

This is the first new dedicated trainer account to be established in the North-East region of the USA since the sales territory was created in the first quarter of 2015.

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"This is the third new dedicated trainer account established this year and the ninth in total. It is another key step towards our strategy of building, by mid-2016, a strong platform for future national roll-out of ODM in the key US market."